Swiss biotechnology company Roche Group (SIX: RO, ROG) (OTCQX: RHHBY) announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Roche Digital Pathology Dx (VENTANA DP 200) system.
This enables pathologists to use digital slide images for primary diagnosis, improving healthcare efficiency and patient care, particularly in areas with limited access to specialists.
The system is designed to aid the pathologist in reviewing and interpreting digital images of scanned pathology slides to help diagnose patients.
FDA clearance marks a significant step towards routine clinical use of Roche's digital pathology solutions.
Zhimeng Biopharma's investigational drug gains Phase 2 epilepsy clinical trial approval in China
Sanofi's SAR402663 granted FDA fast track designation for wet AMD
Implantica produces 10,000 RefluxStop units ahead of planned US launch
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amneal's risperidone extended-release injectable suspension approved by US FDA
Brain+ pilot shows Ayla therapy boosts cognitive outcomes in dementia care
Ascelia Pharma files NDA with FDA for liver imaging drug Orviglance
Biophytis secures EMA clearance to advance Phase 2 obesity trial
Valneva reports strong Phase 2 booster results for Lyme disease vaccine candidate VLA15